191 related articles for article (PubMed ID: 19558251)
1. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.
Dore DD; Trivedi AN; Mor V; Lapane KL
Pharmacotherapy; 2009 Jul; 29(7):775-83. PubMed ID: 19558251
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
[TBL] [Abstract][Full Text] [Related]
4. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
5. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
6. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.
Koro CE; Fu Q; Stender M
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):989-96. PubMed ID: 18759378
[TBL] [Abstract][Full Text] [Related]
7. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Tzoulaki I; Molokhia M; Curcin V; Little MP; Millett CJ; Ng A; Hughes RI; Khunti K; Wilkins MR; Majeed A; Elliott P
BMJ; 2009 Dec; 339():b4731. PubMed ID: 19959591
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
11. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Loke YK; Kwok CS; Singh S
BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
[TBL] [Abstract][Full Text] [Related]
12. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
13. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
[TBL] [Abstract][Full Text] [Related]
15. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
16. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
Juurlink DN; Gomes T; Lipscombe LL; Austin PC; Hux JE; Mamdani MM
BMJ; 2009 Aug; 339():b2942. PubMed ID: 19690342
[TBL] [Abstract][Full Text] [Related]
17. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
Douglas IJ; Evans SJ; Pocock S; Smeeth L
PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025
[TBL] [Abstract][Full Text] [Related]
18. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.
Brownstein JS; Murphy SN; Goldfine AB; Grant RW; Sordo M; Gainer V; Colecchi JA; Dubey A; Nathan DM; Glaser JP; Kohane IS
Diabetes Care; 2010 Mar; 33(3):526-31. PubMed ID: 20009093
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
[TBL] [Abstract][Full Text] [Related]
20. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
